BRAF V600E基因突变在结直肠癌治疗中的研究进展  

Advances in the study of BRAF V600E mutation in the treatment of colorectal cancer

作　　者：张祥涛 刘睿清 张宪祥[1] 卢云[1] Zhang Xiangtao;Liu Ruiqing;Zhang Xianxiang;Lu Yun(Second Gastrointestinal Department,Huangdao Hospital,Affiliated Hospital of Qingdao University,Qingdao 266000,China)

机构地区：[1]青岛大学附属医院黄岛院区胃肠外二科,266000

出　　处：《中华结直肠疾病电子杂志》2020年第3期292-295,共4页Chinese Journal of Colorectal Diseases(Electronic Edition)

基　　金：国家自然科学基金青年基金(No.81802473)。

摘　　要：结直肠癌是第三大常见癌症,在全球相关癌症死亡率中排名第四。RAS-RAF-MEK-ERK(MAPK)通路的本构性激活在结直肠癌的发生发展中起着重要作用。V-raf鼠肉瘤毒癌基因同源体B(BRAF)是MAPK信号通路上的激酶,在结直肠癌发展中起重要作用。临床观察发现,约8%~10%的结直肠癌病例中存在BRAF V600E突变,并预示较低的中位生存率,对结直肠癌的预后有预测价值。初步探讨BRAF V600E突变,为结直肠癌的分子靶向治疗提供新的思路。Colorectal cancer is the third most common cancer and the fourth leading cause of cancer-related deaths worldwide.Constitutive activation of Ras-Raf-Mek-Erk(MAPK)pathway plays an important role in the occurrence and development of CRC.V-raf murine sarcoma viral oncogene homolog(BRAF)is a kinase in the MAPK signaling pathway and plays an important role in the development of colorectal cancer.Clinical observations showed that BRAF V600E was found in approximately 8%~10%of CRC cases and was associated with significantly lower median overall survival.It has predictive value for the prognosis of colorectal cancer.A preliminary study on BRAF V600E mutation provides a new idea for molecular targeted therapy of colorectal cancer.

关 键 词：结直肠肿瘤 BRAF突变 MSI 靶向治疗 

分 类 号：R735.34[医药卫生—肿瘤]